LG Life Sciences and Gilead to develop novel drug candidate caspase inhibitor

Published: 2007-11-13 07:00:00

Updated: 2007-11-13 07:00:00

LG Life Sciences says that it signed with Gilead Sciences, Inc. of the United States an exclusive license agreement focused on the development of caspase inhibitors for the treatment of fibrotic diseases. The agreement grants Gilead commercialization rights to LG' caspase inhibitors, including LB...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK